John Dawson CBE, joined Oxford Biomedica’s Board as a Non-Executive Director in August 2008, and was appointed Chief Executive Officer from October 2008 until January 2022. Prior to this he held senior management positions in the European operations of Cephalon Inc., including Chief Financial Officer and Head of Business Development Europe. While at Cephalon he led many deals building the European business to over 1,000 people and to a turnover of several hundred million US dollars.
September 8, 2022
CS Pharmaceuticals Ltd (“CSP” or “the Company”), a specialty pharmaceutical company focussed on the in-license of China rights of innovative products and the development and commercialisation of them…